Results 21 to 30 of about 28,675 (247)

Use and cost of disease-modifying therapies by Sonya Slifka Study participants: has anything really changed since 2000 and 2009?

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019
Background Disease-modifying therapies benefit individuals with relapsing forms of multiple sclerosis, but their utility remains unclear for those without relapses.
Sarah L Minden, R Philip Kinkel, Helene T Machado, Jonathan S Levin, Meredith B Rosenthal, Lisa I Iezzoni   +5 more
doaj   +1 more source

Different cognitive profiles of Brazilian patients with relapsing-remitting and primary progressive multiple sclerosis

Arquivos de Neuro-Psiquiatria, 2011
Cognitive impairment is a symptom of multiple sclerosis (MS). Different clinical forms of multiple sclerosis have different cognitive profiles, according to findings of previous studies which used extensive batteries of neuropsychological tests ...
Dóra-Neide Rodrigues, Renata Alves Paes, Claudia Cristina Ferreira Vasconcelos, Jesus Landeira-Fernandez, Maria Papais Alvarenga   +4 more
doaj   +1 more source

Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018
Background Disease-modifying therapies are thought to reduce the conversion rate to secondary progressive multiple sclerosis. Objective To explore the rate, chronology, and contributing factors of conversion to the progressive phase in treated relapsing ...
Francisco Coret, Francisco C Pérez-Miralles, Francisco Gascón, Carmen Alcalá, Arantxa Navarré, Ana Bernad, Isabel Boscá, Matilde Escutia, Sara Gil-Perotin, Bonaventura Casanova   +9 more
doaj   +1 more source

Thalamic neurodegeneration in relapsing-remitting multiple sclerosis

Neurology, 2003
To define the extent of neuronal injury and loss in thalamic gray matter in patients with relapsing-remitting (RR) MS and to characterize how these neuronal pathologic changes are related to disease duration.The authors studied 14 patients with RRMS (Expanded Disability Status Scale score, mean 3.25, range 2.0 to 6.0) and 14 (8 men, 6 women) age ...
A. CIFELLI, M. WYLEZINSKA, P. JEZZARD, J. PALACE, ALECCI, MARCELLO, P. MATTHEWS   +5 more
openaire   +5 more sources

Faster progression to multiple sclerosis disability is linked to neuronal pathways associated with neurodegeneration: An ethnicity study.

PLoS ONE, 2023
Although the causes of multiple sclerosis are largely unknown, genetic and environmental components play an important role. Geographic distribution, varying with latitude, reflects both genetic and environmental influences.
Gil Harari, Michael Gurevich, Mark Dolev, Rina Zilkha Falb, Anat Achiron   +4 more
doaj   +1 more source

Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: A multicentre Italian wearable tracker study

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2023
Background Sleep disorders are common in patients with multiple sclerosis and have a bidirectional interplay with fatigue and depression. Objective To evaluate the effect of treatment with oral dimethyl fumarate on the quality of sleep in relapsing ...
Giancarlo Comi, Letizia Leocani, Luigi Ferini-Strambi, Marta Radaelli, Gloria D Costa, Roberta Lanzillo, Giacomo Lus, Valentina Bianchi, Sebastiano Traccis, Fioravante Capone, Luigi ME Grimaldi, Giuseppe Salemi, Alessandra Cardillo, Valentina Zipoli,   +14 more
doaj   +1 more source

Dimethyl fumarate for relapsing-remitting multiple sclerosis [PDF]

The Lancet Neurology, 2014
For many years the only drugs licensed for the treatment of multiple sclerosis (MS) were administered by injection (interferon beta, glatiramer and ▼natalizumab). Recently, three oral drugs have become available. We have previously reviewed the use of ▼fingolimod for highly active relapsing-remitting MS1 and ▼teriflunomide for the management of ...
Martyn J, Burke, Joanna, Richardson, Elisabeth, George, Amanda I, Adler   +3 more
openaire   +4 more sources

Segmented corpus callosum diffusivity correlates with the Expanded Disability Status Scale score in the early stages of relapsing-remitting multiple sclerosis

Clinics, 2013
OBJECTIVE: The aim of this study was to characterize the microscopic damage to the corpus callosum in relapsing-remitting multiple sclerosis (RRMS) with diffusion tensor imaging and to investigate the correlation of this damage with disability.
Carolina de Medeiros Rimkus, Thiago de Faria Junqueira, Dagoberto Callegaro, Maria Concepcion Garcia Otaduy, Claudia da Costa Leite   +4 more
doaj   +1 more source

Gut microbiome and aging—A dynamic interplay of microbes, metabolites, and the immune system

FEBS Letters, EarlyView.
Age‐dependent shifts in microbial communities engender shifts in microbial metabolite profiles. These in turn drive shifts in barrier surface permeability of the gut and brain and induce immune activation. When paired with preexisting age‐related chronic inflammation this increases the risk of neuroinflammation and neurodegenerative diseases.
Aaron Mehl, Eran Blacher
wiley   +1 more source

Correlations between hippocampal functional connectivity, structural changes, and clinical data in patients with relapsing-remitting multiple sclerosis: a case-control study using multimodal magnetic resonance imaging

Neural Regeneration Research, 2022
Multiple sclerosis is associated with structural and functional brain alterations leading to cognitive impairments across multiple domains including attention, memory, and the speed of information processing.
Xin-Quan Gu, Ying Liu, Jie-Bing Gu, Lin-Fang Li, Ling-Ling Fu, Xue-Mei Han   +5 more
doaj   +1 more source